The Quantellect read.As of Nov 20, 2026, 13 active firms cover Charles River Laboratories: 11 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $219.00 to $357.00, a moderate spread. The average target of $314.38 sits 4% below the current $328.02. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 10 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.87 next quarter toward $12.97 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy1185%
Neutral215%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$314.38
-4.2% downside
Average target across 13 active firms as of Nov 20, 2026 vs $328.02 current
Highest Target$357.00
Average Target$314.38
Lowest Target$219.00
Detailed analyst forecasts for CRL
Showing 1–14 of 14 named analysts shown · 13 active firms in the rating projection
As of Nov 20, 2026, 11 of 13 active firms rate CRL a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRL EPS & revenue forecast
EPS · NEXT QUARTER
$2.87
Range $2.48 – $3.13 · 7 analysts · +39% YoY
Next period, 7 analysts expect Charles River Laboratories to earn $2.87 a share (range $2.48 – $3.13), versus $2.06 a year earlier. Full-year consensus is $11.47, growing to $12.97 the year after.
REVENUE · NEXT QUARTER
$991.3M
Range $969.2M – $1.0B · 7 analysts · -0% YoY
Revenue is expected to reach $991.3M (range $969.2M – $1.0B), -0.5% year-over-year. Full-year consensus is $4.0B, rising to $4.1B next year.
Top analysts covering Charles River Laboratories
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRL.
#1
EC
Eric Coldwell
Baird · Rank #127
Buy
$334.00+1.8% to target
Overall win rate
37%
+ Follow
#2
Kevin Caliendo
UBS · Rank #165
Buy
$387.00+18.0% to target
Overall win rate
42%
+ Follow
#3
Luke Sergott
Barclays · Rank #267
Buy
$330.00+0.6% to target
Overall win rate
43%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #448
Buy
$265.00-19.2% to target
Overall win rate
29%
+ Follow
#5
CW
Casey Woodring
JP Morgan
Buy
$385.00+17.4% to target
Coverage
—
+ Follow
CRL stock forecast FAQ
What is CRL's average 12-month price target?+
The 13 active firms with a live target average $314.38 for Charles River Laboratories over the next 12 months, ranging from a $357.00 high to a $219.00 low, as of Nov 20, 2026.
Is CRL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 20, 2026, 11 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRL?+
The Street-high target is $357.00 (UBS), and the Street-low is $219.00 (CLSA). The average of all 13 active-firm targets is $314.38.
How many active Wall Street firms cover CRL?+
13 active firms have a recognized rating on Charles River Laboratories as of Nov 20, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRL?+
Among analysts who currently cover CRL, Eric Coldwell of Baird has the strongest overall Quantellect track record (Rank #127). Their current call is Buy with a $334.00 target.
What is Charles River Laboratories's projected EPS for next quarter?+
The consensus estimate is $2.87 per share (range $2.48 – $3.13) across 7 analysts. Full-year EPS is projected at $11.47, rising to $12.97 the following year.
How much revenue is Charles River Laboratories expected to report next quarter?+
Consensus revenue is $991.3M (range $969.2M – $1.0B). Full-year revenue is projected at $4.0B, growing to $4.1B next year.
Have analysts been upgrading or downgrading CRL lately?+
As of Nov 20, 2026, 11 of 13 active firms rate CRL a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.